| Date Filed | Type | Description |
| 07/26/2018 |
GN
| Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018 |
| 07/17/2018 |
GN
| Immune Pharmaceuticals Announces Filing of Proxy Statement for Reverse Stock Split |
| 06/08/2018 |
GN
| Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determination |
| 05/23/2018 |
GN
| Immune Pharmaceuticals Provides a Pipeline Update |
| 05/07/2018 |
GN
| Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc. |
| 05/07/2018 |
GN
| Market Trends Toward New Normal in The AES, Immune Pharmaceuticals, Hercules Capital, Zendesk, Chevron, and Cornerstone OnDemand — Emerging Consolidated Expectations, Analyst Ratings |
| 11/15/2017 |
BW
| Immune Pharmaceuticals Announces Third Quarter 2017 Financial Results and Provides a Corporate Update |
| 10/19/2017 |
BW
| Immune Pharmaceuticals Inc. Announces Pricing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants |
| 07/19/2017 |
BW
| Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company |
| 08/14/2011 |
BW
| EpiCept Corporation Reports Second Quarter 2011 Financial Results and Provides Business Update |
| 07/17/2011 |
BW
| EpiCept Corporation Announces Publication in Journal Blood of a New Meta-Analysis Examining Lack of Efficacy of Interleukin-2 as Monotherapy in AML Remission Maintenance |
| 06/28/2011 |
BW
| EpiCept Corporation Announces Reconvened Stockholders' Meeting Results |
| 06/26/2011 |
BW
| EpiCept Receives Initial FDA Comments on Application for Ceplene® Special Protocol Assessment |
| 06/19/2011 |
BW
| EpiCept Corporation Announces Stockholders' Meeting Results and Adjournment |
| 06/06/2011 |
BW
| EpiCept Receives Positive Nasdaq Panel Decision |
| 05/30/2011 |
BW
| EpiCept Obtains New $10.6 Million Secured Debt Financing; Prepays Outstanding Convertible Notes |
| 05/19/2011 |
BW
| EpiCept to Present at the 18th Annual Euro-Biotech Forum |
| 05/09/2011 |
BW
| EpiCept Corporation Reports First Quarter 2011 Financial Results and Provides Business Update |
| 05/09/2011 |
BW
| EpiCept Files Protocol with FDA for Ceplene® Phase III Confirmatory Trial |
| 05/04/2011 |
BW
| EpiCept to Report First Quarter 2011 Operating and Financial Results on May 10, 2011 |
| 05/02/2011 |
BW
| Notice of the Annual Meeting of Stockholders of EpiCept Corporation |
| 04/27/2011 |
BW
| EpiCept's Board of Directors Appoints New Independent Member |
| 04/08/2011 |
BW
| EpiCept Receives Nasdaq Staff Determination Letter |
| 03/28/2011 |
BW
| EpiCept to Raise $4.6 Million in Registered Direct Offering |
| 03/27/2011 |
BW
| EpiCept to Present at the Bio Windhover/Pharmaceutical Strategic Outlook 2011 Conference |
| 03/03/2011 |
BW
| EpiCept to Present at the Cowen and Company 31st Annual Healthcare Conference |
| 03/03/2011 |
BW
| EpiCept Identifies Ceplene® Survival Benefit in Key AML Subgroup |
| 02/24/2011 |
BW
| EpiCept Reports Fourth Quarter and Full Year 2010 Operating and Financial Results |
| 02/23/2011 |
BW
| EpiCept to Present at The Wall Street Analyst Forum 22nd Annual Investor Conference |
| 02/18/2011 |
BW
| EpiCept to Report Fourth Quarter and Full Year 2010 Operating and Financial Results on February 24, 2011 |
| 02/16/2011 |
BW
| EpiCept to Present at the Lippert/Heilshorn Life Sciences & MedTech Virtual Conference on February 17 |
| 12/15/2010 |
BW
| EpiCept Announces Initiation by NCI of Phase II Trial with Crolibulin™ in Anaplastic Thyroid Cancer |
| 12/10/2010 |
BW
| EpiCept Reports New Analysis Supports Ceplene's Favorable Impact on Overall Survival |
| 12/05/2010 |
BW
| EpiCept Announces Ceplene® Poster Presentation at the 52nd Annual Meeting of the American Society of Hematology |
|